Metastatic hormone-sensitive prostate cancer with high tumor load research hub

One multicenter, randomized, open, phase III clinical study on SHR3680 combined with androgen deprived therapy (ADT) versus Bicalutamide combined with ADT in treatment of metastatic hormone-sensitive prostate cancer with high tumor load.

This study is looking at a new treatment called SHR3680 for men with prostate cancer that has spread. It compares SHR3680 plus standard hormone therapy against another common treatment, Bicalutamide, plus standard hormone therapy, to see which works better and is safer.